Esbriet: payments to doctors
Payments that named Esbriet as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.7M
- Providers
- 5,014
- Transactions
- 20,533
- Average per transaction
- $82
The per-transaction average — $82 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,014 providers the average total is $338, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $1,426,868 | 84.3% |
| F. Hoffmann-la Roche AG | $229,558 | 13.6% |
| Hoffmann-la Roche Limited | $21,568 | 1.3% |
| Genentech, Inc. | $14,291 | 0.8% |